Table 1.
EpiC and SIDHAS technical assistance activities to scale up MMD among CALHIV.
Fig 1.
Proportion of CALHIV ages 2–18 years receiving MMD among those currently on ART at 36 SIDHAS-supported sites in Akwa Ibom and Cross River states, Nigeria, by quarter (October 2019–March 2021).
Fig 2.
Number and proportion of CALHIV on MMD among those currently on ART at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).
Table 2.
Number of CALHIV currently on ART at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).
Fig 3.
Proportion of CALHIV on MMD among those currently on ART at 36 SIDHAS-supported sites, by ARV supply and age group (October–December 2019 vs. January–March 2021).
Table 3.
Proportion of CALHIV at 36 SIDHAS-supported sites who had a documented VL test within the past 12 months among those currently on treatment for at least six months, by age group and quarter (April 2019–March 2021).
Fig 4.
Proportion of virally suppressed CALHIV among those with a VL test result within the past 12 months at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).
Table 4.
Number of CALHIV with a VL test result within the past 12 months at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).
Fig 5.
Proportion of CALHIV ages 2–18 years currently on ART, on optimized pediatric regimens, on MMD, and virally suppressed at 36 SIDHAS-supported sites, by quarter (October 2019–March 2021).
Fig 6.
Proportion of CALHIV currently on ART, on optimized pediatric regimens, and virally suppressed at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).
Fig 7.
Proportion of CALHIV currently on ART on optimized pediatric regimens and on MMD at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).
Table 5.
Months of stock by pediatric ARV medication at 36 SIDHAS-supported sites (October–December 2019 vs. January–March 2021).
Fig 8.
Proportion of CALHIV ages 2–18 years currently on ART, enrolled in CAGs, and on MMD at 36 SIDHAS-supported sites, by quarter (October 2019–March 2021).
Fig 9.
Proportion of CALHIV on MMD among those currently on ART at 36 SIDHAS-supported sites, by age group January–March 2021 (endline) vs. June–September 2021.